Drug Profile
Research programme: vaccines - Matrivax
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Matrivax
- Class Bacterial polysaccharides; Bacterial vaccines; Meningococcal vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Clostridium difficile infections; Meningococcal infections; Pneumococcal infections
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Clostridium-difficile-infections(Prevention) in USA
- 28 Mar 2022 No recent reports of development identified for preclinical development in Meningococcal-infections(Prevention) in USA
- 28 Mar 2022 No recent reports of development identified for preclinical development in Pneumococcal-infections(Prevention) in USA